An　endogenous　time-keeping　system　found　in　all　kingdoms　of　life,　the　endogenous　circadian　clock,　is　the　source　of　the　essential　cyclic　change　mechanism　known　as　the　circadian　rhythm.　The　primary　circadian　clock　that　synchronizes　peripheral　circadian　clocks　to　the　proper　phase　is　housed　in　the　anterior　hypothalamus＇s　suprachiasmatic　nuclei　(SCN),　which　functions　as　a　central　pacemaker.　According　to　many　epidemiological　studies,　many　cancer　types,　especially　brain　tumors,　have　shown　evidence　of　dysregulated　clock　gene　expression,　and　the　connection　between　clock　and　brain　tumors　is　highly　specific.　In　some　studies,　it　is　reported　that　the　treatment　administered　in　the　morning　has　been　linked　to　prolonged　survival　for　brain　cancer　patients,　and　drug　sensitivity　and　gene　expression　in　gliomas　follow　daily　rhythms.　These　results　suggest　a　relationship　between　the　circadian　rhythm　and　the　onset　and　spread　of　brain　tumors,　while　further　accumulation　of　research　evidence　will　be　needed　to　establish　definitely　these　positive　outcomes　as　well　as　to　determine　the　mechanism　underlying　them.　Chronotherapy　provides　a　means　of　harnessing　current　medicines　to　prolong　patients＇　lifespans　and　improve　their　quality　of　life,　indicating　the　significance　of　circadian　rhythm　in　enhancing　the　design　of　future　patient　care　and　clinical　trials.　Moreover,　it　is　implicated　that　chronobiological　therapy　target　may　provide　a　significant　challenge　that　warrants　extensive　effort　to　achieve.　This　review　examines　evidence　of　the　relationship　of　circadian　rhythm　with　glioma　molecular　pathogenesis　and　summarizes　the　mechanisms　and　drugs　implicated　in　this　disease.